GlassScriptPhysician profile
Amy Horner
NPI 1164430740
$7,625.23
in general payments reported to CMS, 2019-2025
28 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $786 · 2022: $1,810 · 2023: $2,263 · 2024: $1,570 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,930 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,929.57 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,286.49 | 2021-2025 | |
| Janssen Biotech, INC. | $854.08 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $649.42 | 2021-2025 | Taltz, Olumiant, Zepbound |
| Amgen INC. | $549.21 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $538.93 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $485.12 | 2021-2025 | |
| Genzyme Corporation | $461.81 | 2021-2025 | |
| Ucb, INC. | $428.44 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $417.99 | 2022-2025 | Ilumya, Winlevi, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $255.19 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $255.17 | 2021-2024 | Adbry |
| Allergan, INC. | $219.95 | 2021-2022 | |
| Galderma Laboratories, L.P. | $199.06 | 2021-2025 | Nemluvio |
| Pfizer INC. | $189.31 | 2021-2024 | |
| Dermavant Sciences, INC. | $184.61 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $131.10 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.22 | 2024 | Spevigo |
| Almirall LLC | $85.83 | 2022-2023 | Seysara |
| Mayne Pharma Commercial LLC | $56.09 | 2023 | |
| Organon LLC | $48.07 | 2024 | |
| Arcutis Biotherapeutics, INC. | $41.34 | 2023 | |
| Genentech USA, INC. | $40.67 | 2021 | |
| Journey Medical Corporation | $33.88 | 2022-2025 | |
| Verrica Pharmaceuticals INC. | $33.62 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.98 | 2022-2023 | Jublia |
| Fresenius Kabi USA, LLC | $24.69 | 2023 | |
| Surgenex LLC | $18.41 | 2025 | Surmatrix, Renograft, Ardeograft |
| Teva Pharmaceuticals USA, INC. | $16.55 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Horner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.